According to Spherix Global Insights, rheumatologists and nephrologists are excited about new treatment options in addition to a multitude of...
US dermatologists’ lack of satisfaction with current treatment options in hidradenitis suppurativa and alopecia areata paves the way for advanced...
Entyvio SC and Remsima SC have experienced noteworthy uptake since their launches in 2020 and are positioned for continued success...
AbbVie’s Skyrizi now garners the greatest switch-to rate, capturing the majority of new business from patients previously treated with sister-brand...
Infliximab and adalimumab biosimilars continue to increase their presence in ulcerative colitis and Crohn’s disease therapy switching, while Entyvio SC...
Spherix Global Insights and Fraser Healthcare are partnering to shed light in this evolving landscape with a new service that...
According to Spherix Global Insights, nephrologists overwhelmingly chose the DAPA-CKD trial as the most compelling among the eight presented during...
With both steroid-based and advanced therapies poised for FDA approval in the near term, gastroenterologists’ general satisfaction with current eosinophilic...
Will impressive uptake of Novartis’ Mayzent in the active secondary progressive multiple sclerosis market over the past two years be...
The Philadelphia Business Journal and The Entrepreneurs’ Forum of Greater Philadelphia have recognized Spherix for the second year in a...
Lupus has high unmet needs and a very active pipeline, including AstraZeneca’s anifrolumab, Eli Lilly’s Olumiant, novel TYK-2 inhibitors from...
A newly published report by Spherix Global Insights includes the responses of 216 gastroenterologists and 1,026 audited patient records in...
